Krishnan A, Mukherjee D. Prognostic value of coagulation markers in locally advanced gastric cancer following neoadjuvant immunochemotherapy. World J Gastrointest Oncol 2025; 17(8): 105099 [DOI: 10.4251/wjgo.v17.i8.105099]
Corresponding Author of This Article
Arunkumar Krishnan, Department of Supportive Oncology, Atrium Health Levine Cancer, 1021 Morehead Medical Drive, Charlotte, NC 28204, United States. dr.arunkumar.krishnan@gmail.com
Research Domain of This Article
Oncology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Aug 15, 2025; 17(8): 105099 Published online Aug 15, 2025. doi: 10.4251/wjgo.v17.i8.105099
Prognostic value of coagulation markers in locally advanced gastric cancer following neoadjuvant immunochemotherapy
Arunkumar Krishnan, Diptasree Mukherjee
Arunkumar Krishnan, Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27103, United States
Arunkumar Krishnan, Department of Supportive Oncology, Atrium Health Levine Cancer, Charlotte, NC 28204, United States
Diptasree Mukherjee, Department of Medicine, Apex Institute of Medical Science, Kolkata 700075, West Bengal, India
Author contributions: Krishnan A contributed to the concept of the study, drafted the manuscript, and participated in the review and editing. All authors were involved in critically reviewing the manuscript for important intellectual content. All authors reviewed and approved the final version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Arunkumar Krishnan, Department of Supportive Oncology, Atrium Health Levine Cancer, 1021 Morehead Medical Drive, Charlotte, NC 28204, United States. dr.arunkumar.krishnan@gmail.com
Received: January 16, 2025 Revised: March 11, 2025 Accepted: March 21, 2025 Published online: August 15, 2025 Processing time: 215 Days and 11.4 Hours
Core Tip
Core Tip: Gastric cancer (GC) has a high mortality-to-incidence ratio. Noninvasive biomarkers promise early detection, monitoring, and personalized treatment strategies. A recent study by Li et al examined whether hypercoagulation is an effective prognostic indicator in locally advanced GC patients who underwent radical resection after neoadjuvant immunochemotherapy. Future research should implement a multicenter approach to improve applicability. Additionally, considering important confounders such as systemic inflammation, nutrition, and immune responses would deepen our understanding of the association between hypercoagulation and outcomes. Advanced methods such as machine learning and imaging techniques could improve predictive models, allowing clinicians to treat patients more effectively.
